Spexis AG (SIX: SPEX), an Allschwil, Switzerland-based clinical-stage biopharmaceutical company, announced a capital commitment totaling USD $2.5m.
The capital commitment will be in the form of USD $1.0m in secured, interest-bearing debt with partial warrant coverage from SGI and USD $1.5m subordinated debt mandatorily converting into equity from institutional investors. Backers included SPRIM Global Investments (SGI) and institutional investors.
The company intends to use the funds for the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.
Led by Jeff Wager, M.D., Chairman & CEO, Spexis is a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology.
FinSMEs
15/08/2023